跳至主要内容
临床试验/NCT00876070
NCT00876070已完成不适用

Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

SCRI Development Innovations, LLC2 个研究点 分布在 1 个国家目标入组 198 人开始时间: 2008年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
198
试验地点
2
主要终点
Describe patient demographics, disease and treatment characteristics.

研究概览

简要总结

This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients that have received Abraxane chemotherapy greater than three months from the time of chart review.
  • Patients that have received taxane chemotherapy greater than three months from the time of chart review.

排除标准

  • 未提供

结局指标

主要结局

Describe patient demographics, disease and treatment characteristics.

时间窗: 6 months

次要结局

  • Describe detailed treatment and response characteristics.(6 months)
  • Describe resource utilization and cost variables.(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验